Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Combining Human Urinary Kallidinogenase with Endovascular Therapy for Acute Ischemic Stroke

Official title: Efficacy and Safety of Human Urinary Kallidinogenase Combined With Endovascular Therapy in Acute Ischemic Stroke With Large Vessel Occlusion: A Prospective, Randomized, Double-blind, Placebo-controlled, Multi-center Study

Run by Huashan Hospital · NCT06211712 · Data updated 2026-11-12

This study is testing if adding a new treatment called Human Urinary Kallidinogenase to standard endovascular therapy can help people who have had a severe stroke caused by a blocked blood vessel.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment120 (estimated)
SponsorHuashan Hospital
Academic / other
Locations1 site (Shanghai)
StatusRecruiting
StartedApril 17, 2024
Main results expectedJune 2025
Study endsDecember 2025
Registry record updatedDecember 4, 2024
Trial IDNCT06211712 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 18 and older who have experienced an acute anterior circulation ischemic stroke and are receiving endovascular treatment within 24 hours.

Probably not a fit

Patients with severe organ dysfunction, coagulation disorders, or contraindications to the treatment will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the safety and efficacy of Human Urinary Kallidinogenase when used alongside endovascular therapy in patients suffering from acute ischemic stroke due to large vessel occlusion. It is a prospective, randomized, double-blind, placebo-controlled, multi-center trial involving approximately 120 participants. Patients will be assigned to receive either the experimental treatment or a placebo for a duration of 10 days, with primary efficacy assessed at 90 days post-treatment. Safety evaluations will also be conducted over the same period.

Why it matters

Potential benefit: If successful, this treatment could significantly improve recovery outcomes for patients with acute ischemic stroke.

How similar studies have gone: While this approach is innovative, similar studies have shown promise in the treatment of acute ischemic stroke, suggesting potential for success.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Participant with acute anterior circulation ischemic stroke receiving endovascular treatment within 24 hours (non-bridged).
2. Age ≥18 years old.
3. The mRS score was 0-1 before onset.
4. ASPECT score of infarction on emergency CT ≥7.
5. Emergency CTA indicating AIS with large vessel occlusion (internal carotid artery, M1 or M2 segment of middle cerebral artery).
6. Emergency CTP or DWI suggesting infarct core body ≥10 mL and \<100 mL, and low perfusion brain tissue volume/ infarct core volume\> 1.2.
7. Participant is willing and able to comply with the study protocol, and sign the informed consent form (patient or surrogate).

Exclusion Criteria:

1. Participant with severe heart, liver and kidney dysfunction, coagulation dysfunction, intolerance to surgery, Human Urinary Kallidinogenase allergy, contrast agent allergy or other angiographic contraindications.
2. CT or MRI showed intracranial hemorrhagic diseases (such as hemorrhagic stroke, epidural hematoma, intracranial hematoma, intraventricular hemorrhage, subarachnoid hemorrhage, etc.).
3. Participant with previous cerebral hemorrhage, brain tumor, brain trauma or other brain diseases.
4. Taking ACEI antihypertensive drugs regularly and could not stop.
5. Participant with major surgery or severe trauma in the past 2 weeks.
6. Poor compliance and cannot fully follow the study protocol.
7. Pregnancy or lactation.

Where it's running

  • Huashan Hospital
    Shanghai, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.